Epstein-Barr 바이러스 유행지역에서 두경부암 발생과의 연관성
Association of Epstein-Barr Virus and Head and Neck Cancer in an Endemic Area
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Abstract
Background and Objectives：A number of reports have suggested that Epstein-Barr virus (EBV) is associated with different forms of head and neck cancers (HNC) such as nasopharyngeal carcinoma, NK/T cell lymphoma and Burkitts lymphoma. We evaluated the association of EBV with HNC as a causative factor in an endemic area of the virus. Subjects and Method：Fresh specimens of HNC were obtained from 72 new patients between August 2003 and January 2005. In situ hybridization for EBER was performed with immunohistochemical staining of p53, Bcl-2 and LMP-1 and serologic tests on anti-viral capsid antigen (VCA) and anti-early antigen (EA)-D. The results of EBV positivity were analyzed according to tumor TNM stages, sites, pathology and smoking status. A correlation between EBV positivity and p53, Bcl-2, LMP-1 positive staining was investigated. Results：Nine (12% ) of the total 72 patients showed EBV positivity of tumor, depending mainly on pathology and sites, but not tumor staging, age, sex or smoking status：NPC (3), NK/T cell lymphoma (5), lymphoephithelial carcinoma of the parotid gland (1). All patients had sero-positivity of anti-VCA IgG but not anti-VCA IgM and anti-EA-D. There was a relationship between the presence of EBV, its oncoprotein (LMP-1) and oncogene (Bcl-2). Conclusion：Overall, the incidence of EBV positivity of HNC in an endemic area is not significantly different from the prior reports about non-endemic area. The associa-tion between EBV and LMP-1 or Bcl-2 may be helpful for understanding the role of viral oncogenes in the HNC. (Korean J Otolaryngol 2007 ;50 :235-9)
참고문헌 (20)
- Rickinson AB, "Epstein-Barr virus", pp.2397~2446 (1996), Philadelphia: Lippincott-Raven
- Katz BZ, "Latent and replicating forms ofEpstein-Barr virus DNA in lymphomas and lymphoproliferative diseases", pp.589~98
- Leung SY, "Epstein-Barr virus is present in a wide histological spectrum of sinonasal carcinomas", 19, pp.994~1001 (1995)
- Iezzoni JC, "The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas", 103, pp.308~315 (1995)
- Pathmanathan R, "Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx", 146, pp.1355~1367 (1995)
- Shimakage M, "Association of Epstein-Barr virus with oral cancers", 33, pp.608~614 (2002)
- Kobayashi I, "Prevalence of Epstein-Barr virus in oral squamous cell carcinoma", 189, pp.34~39 (1999)
- Sand LP, "Prevalence of Epstein-Barr virus in oral squamous cell carcinoma, oral lichen planus, and normal oral mucosa", 93(rmal oral mucosa), pp.586~592 (2002)
- Goldenberg D, "Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction", 114, pp.1027~1031 (2004)
- Szkaradkiewicz A, "Epstein-Barr virus and human papillomavirus infections and oropharyngeal squamous cell carcinomas", 2, pp.137~141 (2002)
- Kiaris H, "Detection of Epstein-Barr virus genome in squamous cell carcinomas of the larynx", 10, pp.211~215 (1995)
- Min HK, "Detection andsignificance of human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma and laryngeal squamous cell carcinoma", 39, pp.273~281 (1996)
- Lee JH, "Detection ofEpstein-Barr virus in laryngeal squamous cell carcinoma", 43, pp.306~311 (2000)
- Park JS, "Detection of Epstein Barr virus and HTLV-1 in head and neck lymphomas", 43, pp.1222~1226 (2000)
- "Human oropharyngeal lesionswith a defective Epstein-Barr virus that disrupts viral latency", pp.1349~55
- "Prevalence of Taiwanvariant of Epstein-Barr virus in throat washings from patients withhead and neck tumors in Taiwan", pp.28~31
- "Detectionof Epstein-Barr virus and human papillomavirus in head and necktumors", pp.53~6
- "Detection rates of Epstein-Barr virus from the chronic tonsillitis and its typing", 44, pp.1171~1176 (2001)
- "Induction of bcl-2 expression by Epstein-Barrvirus latent membrane protein 1 protects infected B cells from programmedcell death", pp.1107~15
- "a viral homologue of Bcl-2 protects human B cells from programmed cell death", pp.8479~83